EE200000608A - Farmatseutiline aerosoolpreparaat - Google Patents

Farmatseutiline aerosoolpreparaat

Info

Publication number
EE200000608A
EE200000608A EEP200000608A EEP200000608A EE200000608A EE 200000608 A EE200000608 A EE 200000608A EE P200000608 A EEP200000608 A EE P200000608A EE P200000608 A EEP200000608 A EE P200000608A EE 200000608 A EE200000608 A EE 200000608A
Authority
EE
Estonia
Prior art keywords
aerosol formulation
pharmaceutical aerosol
pharmaceutical
formulation
aerosol
Prior art date
Application number
EEP200000608A
Other languages
English (en)
Estonian (et)
Inventor
Cavaillon Pascal
Llorca Nathalie
Louis Olivier
Rosier Patrick
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000608A publication Critical patent/EE200000608A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000608A 1998-04-18 1999-04-15 Farmatseutiline aerosoolpreparaat EE200000608A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation
PCT/EP1999/002535 WO1999053901A1 (en) 1998-04-18 1999-04-15 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
EE200000608A true EE200000608A (et) 2001-08-15

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000608A EE200000608A (et) 1998-04-18 1999-04-15 Farmatseutiline aerosoolpreparaat

Country Status (30)

Country Link
US (1) US7521042B2 (is)
EP (1) EP1073417B1 (is)
JP (1) JP2002512183A (is)
KR (1) KR20010042816A (is)
CN (1) CN1145478C (is)
AP (1) AP2000001961A0 (is)
AR (1) AR018183A1 (is)
AT (1) ATE228823T1 (is)
AU (1) AU755066B2 (is)
BR (1) BR9909736A (is)
CA (1) CA2328882A1 (is)
CO (1) CO5021210A1 (is)
DE (1) DE69904312T2 (is)
DK (1) DK1073417T3 (is)
EA (1) EA200000956A1 (is)
EE (1) EE200000608A (is)
ES (1) ES2189410T3 (is)
HR (1) HRP20000689A2 (is)
HU (1) HUP0101608A2 (is)
ID (1) ID27887A (is)
IL (1) IL139087A0 (is)
IS (1) IS5665A (is)
MA (1) MA26621A1 (is)
NO (1) NO20005218L (is)
NZ (1) NZ507619A (is)
PE (1) PE20000433A1 (is)
PL (1) PL343491A1 (is)
PT (1) PT1073417E (is)
TR (1) TR200100144T2 (is)
WO (1) WO1999053901A1 (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
PT1169019E (pt) 1999-04-14 2003-07-31 Glaxo Group Ltd Formulacao farmaceutica em aerossol
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
NZ526059A (en) † 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
KR20050088175A (ko) * 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
MXPA05012467A (es) * 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006086270A1 (en) * 2005-02-10 2006-08-17 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
DK2054042T3 (da) 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2393488B1 (en) 2009-02-06 2019-06-19 University Of Southern California Therapeutic compositions comprising monoterpenes
LT2400950T (lt) 2009-02-26 2019-08-26 Glaxo Group Limited Farmacinės kompozicijos, apimančios 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzil)oksi]etoksi}heksil)amino]-1-hidroksetil}-2-(hidroksimetil)fenolį
DK2453894T3 (en) 2009-07-15 2016-01-25 Theravance Biopharma R&D Ip Llc Crystalline free base of a biphenyl compound
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2542082B8 (en) 2010-03-03 2020-06-17 Neonc Technologies Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol
EP2570120B1 (en) * 2010-06-08 2017-10-25 Kobe Gakuin Educational Foundation Coated particle and method for producing coated particle
DK3685835T3 (da) 2010-08-27 2025-07-21 Univ Southern California Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
EP2819645A2 (en) * 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
DK3142701T3 (en) 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
JP6674957B2 (ja) 2015-02-12 2020-04-01 ネオンク テクノロジーズ インク． ペリリルアルコール誘導体を含む医薬組成物
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
EP3547836B1 (en) 2016-11-30 2024-08-21 University of Southern California A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
CN111936125B (zh) 2018-02-08 2025-03-04 南加州大学 穿透血脑屏障的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
EP0257915B1 (en) * 1986-08-11 1993-03-10 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
EP0834314B1 (en) * 1995-06-12 2003-01-15 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6077543A (en) * 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients

Also Published As

Publication number Publication date
DE69904312T2 (de) 2003-10-16
CN1305369A (zh) 2001-07-25
MA26621A1 (fr) 2004-12-20
EP1073417A1 (en) 2001-02-07
DK1073417T3 (da) 2003-03-24
ID27887A (id) 2001-05-03
NZ507619A (en) 2003-05-30
PL343491A1 (en) 2001-08-27
NO20005218D0 (no) 2000-10-17
PT1073417E (pt) 2003-04-30
DE69904312D1 (de) 2003-01-16
HRP20000689A2 (en) 2001-02-28
CA2328882A1 (en) 1999-10-28
TR200100144T2 (tr) 2001-06-21
JP2002512183A (ja) 2002-04-23
BR9909736A (pt) 2000-12-19
WO1999053901A1 (en) 1999-10-28
US7521042B2 (en) 2009-04-21
ATE228823T1 (de) 2002-12-15
AR018183A1 (es) 2001-10-31
IS5665A (is) 2000-10-13
CN1145478C (zh) 2004-04-14
CO5021210A1 (es) 2001-03-27
ES2189410T3 (es) 2003-07-01
AU755066B2 (en) 2002-12-05
EA200000956A1 (ru) 2001-04-23
EP1073417B1 (en) 2002-12-04
AP2000001961A0 (en) 2000-12-31
KR20010042816A (ko) 2001-05-25
NO20005218L (no) 2000-11-10
US20030157032A1 (en) 2003-08-21
HUP0101608A2 (hu) 2002-03-28
PE20000433A1 (es) 2000-05-26
IL139087A0 (en) 2001-11-25
AU3523199A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
DK1073417T3 (da) Farmaceutisk aerosolformulering
EE03664B1 (et) Farmatseutilised aerosoolkompositsioonid
ID24654A (id) Formulasi farmasi omeprazola
NO992339D0 (no) Farmas°ytiske formuleringer
NO20012915L (no) Ny farmasöytisk formulering
DE69530325D1 (de) Aerosol-arzneiformulierungen
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
ID30032A (id) Formulasi farmasi
IS5184A (is) Lyfjasamsetningar
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200000330A (et) Farmatseutilised kompositsioonid
ID25972A (id) Formulasi aerosol pestisida
NO20004816D0 (no) Ny farmasøytisk formulering
NO994436D0 (no) Farmasöytiske sammensetninger
SE9803952D0 (sv) Pharmaceutical formulation
DK1037604T3 (da) Farmaceutiske aerosolsammensætninger
GB9814709D0 (en) Pharmaceutical aerosol formulation
GB9808152D0 (en) Pharmaceutical aerosol formulation
SI1073417T1 (en) Pharmaceutical aerosol formulation
SE9600141D0 (sv) Pharmaceutical formulation